Authors finally evaluated the impact of Zharp1-211 on the GVL effect in B6 recipients receiving acute promyelocytic leukemia (APL) cells, which are driven by the PML-RARA fusion gene and recapitulate the human disease. The gene discussed is PML; the disease is acute promyelocytic leukemia.